Tesamorelin safety, side effects and monitoring
Tesamorelin is a GHRH analogue and — importantly — one of the few peptides in this category that is <b>genuinely FDA-approved</b>, though for a narrow indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is marketed as Egrifta. Everything else it is sold for is off-label.
Safety profile
Injection-site reactions, joint pain, muscle pain, peripheral oedema and — significantly — glucose intolerance. Tesamorelin can worsen blood-sugar control, which matters a great deal in a population that overlaps with metabolic disease. It is contraindicated in active malignancy, pituitary disorders and pregnancy. Fasting glucose and HbA1c should be monitored.
Monitoring
A legitimate programme establishes a baseline before it ships anything. For Tesamorelin, ask what will be measured before you start, at what interval it will be re-measured, and what result would indicate the treatment is not working — a provider who cannot answer the last question has no plan for stopping.
Questions to ask
- Am I receiving FDA-approved Egrifta, or a compounded preparation? They are not the same thing.
- Do I actually have the indication it is approved for?
- How will my blood glucose and HbA1c be monitored?
- What is the evidence for my specific goal, as opposed to the approved one?
- What happens when I stop?
Questions to ask about the pharmacy
The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact substance, salt form and concentration? Get it in writing, and check the substance’s status on our peptide status table.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.
Frequently asked questions
What does Tesamorelin cost through telehealth?
We have not verified a market price. On October 15, 2026, the Egrifta WR website published no list price, describing co-pay and patient assistance programs instead, and Oak Longevity priced tesamorelin only after an assessment. Ask for the total cost in writing, and ask whether you will get Egrifta WR or a compounded product.
Is Tesamorelin FDA-approved?
Yes, for one use. Egrifta WR is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, and its label says it is not indicated for weight-loss management. Compounded tesamorelin is not the approved product, and other uses are off-label.
Does Tesamorelin work?
FDA approved Egrifta WR on clinical trial evidence in adults with HIV and lipodystrophy. We found no comparable trials for general fat loss, anti-ageing or performance in other people, and approval for one condition is not evidence for another.
Sources
- U.S. Food and Drug Administration — approved labels and compounding guidance for this molecule.
- PubMed / NIH — indexed human clinical literature.
- ClinicalTrials.gov — registered trials, where they exist.
- Our source hierarchy and pricing-verification methodology.